Timber Pharmaceuticals Provides Business Update and Announces Year End 2020 Financial Results
23. März 2021 16:05 ET
|
Timber Pharmaceuticals
50% of patients in the Phase 2b CONTROL study have now been randomized despite COVID-19 disruptions in the trial marketplace Cash Position of $10.4 Million at December 31, 2020 BASKING RIDGE, NJ,...
Timber Pharmaceuticals’ Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer® (TMB-002) in Europe
17. März 2021 08:00 ET
|
Timber Pharmaceuticals
- Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe - Basking Ridge, N.J., March 17, 2021 (GLOBE...
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
15. März 2021 08:30 ET
|
Timber Pharmaceuticals
- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder - Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials...
Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
05. März 2021 08:30 ET
|
Timber Pharmaceuticals
WOODCLIFF LAKE, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on...
Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer
25. Januar 2021 16:05 ET
|
Timber Pharmaceuticals
Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc....
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
12. Januar 2021 16:22 ET
|
Timber Pharmaceuticals
Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022 WOODCLIFF LAKE, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc....
Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001
15. Dezember 2020 08:00 ET
|
Timber Pharmaceuticals
- Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition - WOODCLIFF LAKE, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals,...
Timber Pharmaceuticals Hosts Business Update Conference Call
10. Dezember 2020 08:30 ET
|
Timber Pharmaceuticals
Call to be held on Thursday, December 17th at 11:00am EST WOODCLIFF LAKE, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...
Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main Event Conference
08. Dezember 2020 16:05 ET
|
Timber Pharmaceuticals
Presentation on Tuesday December 15th at 10:40am EST LOS ANGELES, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American:...
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders
20. November 2020 09:05 ET
|
Timber Pharmaceuticals
WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...